Debiopharm Group™ and Biocartis Enter Partnership to Enhance Personalized Medicine
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, announced the signature of an investment agreement with Biocartis.
Financial details are not disclosed. The two partners will furthermore cooperate in the field of companion diagnostics linked to the therapies developed by Debiopharm (in the oncology and infectious diseases areas). Debiopharm’s contribution will be in the field of biomarkers, whilst Biocartis will use its recently created molecular diagnostic platform.
“Debiopharm understood a while ago the increasingly important role that companion diagnostics would play in the future” said Thierry Mauvernay, executive vice-president of Debiopharm Group, who added: ”we are extremely happy not only to have started a new financial partnership with a start-up company, but also to start a cooperation in an area that is extremely relevant and promising from the perspective of personalized medicine and of the responsible use of financial resources. Biocartis, an early stage start-up company, has all the necessary strengths and management know-how to become a leading player in the field of in-vitro-diagnostics. Its potential combined with the disruptive technology it has created is perfectly in line with Debiopharm’s own efforts at the frontline of innovation in life-sciences at large”.
Financial details are not disclosed. The two partners will furthermore cooperate in the field of companion diagnostics linked to the therapies developed by Debiopharm (in the oncology and infectious diseases areas). Debiopharm’s contribution will be in the field of biomarkers, whilst Biocartis will use its recently created molecular diagnostic platform.
“Debiopharm understood a while ago the increasingly important role that companion diagnostics would play in the future” said Thierry Mauvernay, executive vice-president of Debiopharm Group, who added: ”we are extremely happy not only to have started a new financial partnership with a start-up company, but also to start a cooperation in an area that is extremely relevant and promising from the perspective of personalized medicine and of the responsible use of financial resources. Biocartis, an early stage start-up company, has all the necessary strengths and management know-how to become a leading player in the field of in-vitro-diagnostics. Its potential combined with the disruptive technology it has created is perfectly in line with Debiopharm’s own efforts at the frontline of innovation in life-sciences at large”.
